BR112014028121A2 - n-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida - Google Patents
n-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamidaInfo
- Publication number
- BR112014028121A2 BR112014028121A2 BR112014028121A BR112014028121A BR112014028121A2 BR 112014028121 A2 BR112014028121 A2 BR 112014028121A2 BR 112014028121 A BR112014028121 A BR 112014028121A BR 112014028121 A BR112014028121 A BR 112014028121A BR 112014028121 A2 BR112014028121 A2 BR 112014028121A2
- Authority
- BR
- Brazil
- Prior art keywords
- methyl
- pentahydroxyhexyl
- dihydroquinoline
- carboxamide
- oxo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644054P | 2012-05-08 | 2012-05-08 | |
| PCT/US2013/039911 WO2013169746A2 (en) | 2012-05-08 | 2013-05-07 | N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl) amino)-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014028121A2 true BR112014028121A2 (pt) | 2017-06-27 |
Family
ID=49551433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014028121A BR112014028121A2 (pt) | 2012-05-08 | 2013-05-07 | n-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida |
Country Status (19)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013116657A1 (en) | 2012-02-03 | 2013-08-08 | Teva Pharmaceutical Industries Ltd. | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY |
| MX2014009889A (es) | 2012-02-16 | 2014-11-13 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos. |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
| EA201590788A1 (ru) | 2012-11-07 | 2015-12-30 | Тева Фармасьютикал Индастриз Лтд. | Аминные соли лахинимода |
| JP2016514162A (ja) | 2013-03-14 | 2016-05-19 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドナトリウムの結晶およびその製造のための改善された方法 |
| HK1231413A1 (zh) | 2014-04-29 | 2017-12-22 | Teva Pharmaceutical Industries Ltd. | 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2159804A (en) * | 1937-11-23 | 1939-05-23 | Du Pont | N-nitroaryl polyhydroxy alkyl amino compounds and process of preparing the same |
| IE52670B1 (en) | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| US4782155A (en) | 1986-03-19 | 1988-11-01 | Banyu Pharmaceutical Co., Ltd. | Cephalosporin derivatives, processes for their preparation and antibacterial agents |
| SE8902076D0 (sv) | 1989-06-09 | 1989-06-09 | Pharmacia Ab | Derivatives of quinoline-3-carboxanilide |
| US5139878A (en) | 1991-08-12 | 1992-08-18 | Allied-Signal Inc. | Multilayer film constructions |
| US6043006A (en) * | 1997-09-04 | 2000-03-28 | Fuji Photo Film Co., Ltd. | 4-(N,N-dialkylamino)aniline compound, photographic processing composition containing the same and color image-forming method |
| US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| US6121287A (en) | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
| US6133285A (en) | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| EE200100660A (et) | 1999-06-07 | 2003-04-15 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Ravimvorm happe suhtes labiilsete toimeainete jaoks, toimeaine üksus, selle valmistamismeetod ja mikrokerake |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US7560557B2 (en) | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
| US6875869B2 (en) * | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| BRPI0617477A2 (pt) | 2005-10-19 | 2011-07-26 | Teva Pharma | mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica |
| CN101466379B (zh) | 2006-06-12 | 2012-10-31 | 泰华制药工业有限公司 | 稳定的拉喹莫德的制剂 |
| US7528131B2 (en) | 2007-04-19 | 2009-05-05 | Concert Pharmaceuticals Inc. | Substituted morpholinyl compounds |
| WO2009082471A1 (en) * | 2007-12-20 | 2009-07-02 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| AU2009288108B2 (en) | 2008-09-03 | 2013-10-17 | Teva Pharmaceutical Industries, Ltd. | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
| WO2010070449A2 (en) * | 2008-12-17 | 2010-06-24 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| UY32427A (es) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
| EP2228367A1 (en) * | 2009-03-13 | 2010-09-15 | Almirall, S.A. | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors |
| NZ597378A (en) | 2009-06-19 | 2014-08-29 | Teva Pharma | Treatment of multiple sclerosis with laquinimod |
| BR112012002124A2 (pt) | 2009-07-30 | 2015-09-15 | Teva Pharma | tratamento da doença de crohn com laquinimode. |
| WO2011019375A1 (en) | 2009-08-10 | 2011-02-17 | Teva Pharmaceutical Industries Ltd. | Treatment of bdnf-related disorders using laquinimod |
| EA201290860A1 (ru) | 2010-03-03 | 2013-04-30 | Тева Фармасьютикал Индастриз Лтд. | Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата |
| KR20130006640A (ko) | 2010-03-03 | 2013-01-17 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 루푸스 신장염의 치료 |
| US20110217295A1 (en) | 2010-03-03 | 2011-09-08 | Asi Haviv | Treatment of lupus arthritis using laquinimod |
| JP5934202B2 (ja) | 2010-07-09 | 2016-06-15 | テバ ファーマシューティカル インダストリーズ リミティド | 5−クロロ−4−ヒドロキシ−1−メチル−2−オキソ−n−フェニル−1,2−ジヒドロキノリン−3−カルボキサミドと、その塩及びその使用 |
| AU2011274496B2 (en) | 2010-07-09 | 2016-03-10 | Teva Pharmaceutical Industries Ltd. | Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
| JP2012047974A (ja) * | 2010-08-26 | 2012-03-08 | Toshiba Corp | 映像表示装置及び映像表示方法 |
| KR20130065728A (ko) * | 2010-10-14 | 2013-06-19 | 임뮤나르 에이비 | Ahr 활성화제로서의 1,2-디히드로-4-히드록시-2-옥소-퀴놀린-3-카르복사닐리드 |
| PE20140872A1 (es) | 2010-12-07 | 2014-08-09 | Teva Pharma | Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple |
| HK1198278A1 (en) | 2011-07-28 | 2015-03-27 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta |
| SG10201606191PA (en) | 2011-07-28 | 2016-09-29 | Teva Pharma | Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate |
| SG11201401330YA (en) | 2011-10-12 | 2014-05-29 | Teva Pharma | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
-
2013
- 2013-05-02 TW TW102115767A patent/TW201350467A/zh unknown
- 2013-05-07 HK HK15107804.4A patent/HK1207080A1/xx unknown
- 2013-05-07 EA EA201492029A patent/EA201492029A1/ru unknown
- 2013-05-07 UY UY0001034791A patent/UY34791A/es not_active Application Discontinuation
- 2013-05-07 US US13/888,709 patent/US8809537B2/en not_active Expired - Fee Related
- 2013-05-07 NZ NZ630549A patent/NZ630549A/en not_active IP Right Cessation
- 2013-05-07 BR BR112014028121A patent/BR112014028121A2/pt not_active IP Right Cessation
- 2013-05-07 KR KR20147034461A patent/KR20150022816A/ko not_active Withdrawn
- 2013-05-07 CA CA2873258A patent/CA2873258A1/en not_active Abandoned
- 2013-05-07 MX MX2014013664A patent/MX2014013664A/es unknown
- 2013-05-07 SG SG11201407447XA patent/SG11201407447XA/en unknown
- 2013-05-07 EP EP13750833.9A patent/EP2697201A4/en not_active Withdrawn
- 2013-05-07 WO PCT/US2013/039911 patent/WO2013169746A2/en not_active Ceased
- 2013-05-07 AU AU2013259779A patent/AU2013259779B2/en not_active Expired - Fee Related
- 2013-05-07 IN IN2485MUN2014 patent/IN2014MN02485A/en unknown
- 2013-05-07 AR ARP130101569A patent/AR090975A1/es unknown
- 2013-05-07 CN CN201380029448.XA patent/CN104395291B/zh not_active Expired - Fee Related
-
2014
- 2014-10-26 IL IL235338A patent/IL235338A0/en unknown
- 2014-12-02 ZA ZA2014/08825A patent/ZA201408825B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IN2014MN02485A (cg-RX-API-DMAC7.html) | 2015-07-17 |
| CN104395291A (zh) | 2015-03-04 |
| EA201492029A1 (ru) | 2015-06-30 |
| WO2013169746A3 (en) | 2013-12-05 |
| AR090975A1 (es) | 2014-12-17 |
| ZA201408825B (en) | 2016-07-27 |
| MX2014013664A (es) | 2015-04-17 |
| UY34791A (es) | 2013-11-29 |
| CA2873258A1 (en) | 2013-11-14 |
| AU2013259779A1 (en) | 2014-12-18 |
| IL235338A0 (en) | 2014-12-31 |
| SG11201407447XA (en) | 2015-02-27 |
| EP2697201A4 (en) | 2014-11-26 |
| AU2013259779B2 (en) | 2017-06-08 |
| US20130345256A1 (en) | 2013-12-26 |
| HK1207080A1 (en) | 2016-01-22 |
| KR20150022816A (ko) | 2015-03-04 |
| TW201350467A (zh) | 2013-12-16 |
| NZ630549A (en) | 2016-01-29 |
| US8809537B2 (en) | 2014-08-19 |
| EP2697201A2 (en) | 2014-02-19 |
| CN104395291B (zh) | 2017-07-28 |
| WO2013169746A2 (en) | 2013-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019008415A2 (pt) | composto de piridona e inibidor de c-met, composição farmacêutica e uso dos mesmos | |
| BR112015022674A2 (pt) | inibidores de bromodomínio | |
| BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| BR112015032693A2 (pt) | inibidores de bromodomínio | |
| BR112015007061A8 (pt) | composto, composição farmacêutica e uso do composto | |
| BR112016011755A2 (pt) | derivado de ureia ou sal farmacologicamente aceitável do mesmo | |
| BR112015021983A8 (pt) | compostos heterocíclicos, composições e usos dos mesmos | |
| BR112015022643A2 (pt) | inibidores diidro-pirrolpiridinona | |
| BR112015022861A8 (pt) | inibidores de bromodomínio | |
| BR112018068278A2 (pt) | derivado de 3-desóxi e suas composições farmacêuticas | |
| BR112017002811A2 (pt) | compostos de pirrolopirimidina usados como agonista de tlr7 | |
| BR112018008397A2 (pt) | derivados de di-hidroimidazopirazinona úteis no tratamento do câncer | |
| BR112015000704A2 (pt) | imidazotriazinacarbonitrilas úteis como inibidores de quinase | |
| BR112016024545A2 (pt) | derivados de pirazolo pirimidina e seu uso como inibidores de malt1 | |
| BR112014019171A8 (pt) | Composições intranasais de dexdetomida e seus métodos de uso | |
| BR112016016844A2 (pt) | Compostos heterocíclicos | |
| BR112015022551A2 (pt) | inibidores de amido pirrol | |
| BR112016009488A8 (pt) | piperidil-etil-pirimidina substituída, seus usos, e composição farmacêutica. | |
| BR112017019653A2 (pt) | derivados heteroaril bicíclicos fundidos tendo atividade como inibidores de phd | |
| BR112014022214A2 (pt) | fenólicos antibacterianos | |
| BR112015020139A2 (pt) | compostos terapêuticos e usos dos mesmos | |
| BR112015017331A2 (pt) | compostos químicos | |
| BR112015030399B8 (pt) | Derivados heterocíclicos, uso dos referidos derivados e composição farmacêutica para a prevenção ou tratamento de doenças associadas com a ativação da proteína stat3 | |
| BR112016030733A2 (pt) | Derivados de indano e indolina e uso dos mesmos como ativadores de guanilato ciclase solúveis | |
| BR112015022758A2 (pt) | derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2513 DE 06-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |